# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.9...
Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancer...
Truist Securities analyst Robyn Karnauskas reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and maintains $50 price target.
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0...